Patent Issued in Japan Bolsters IP Protection for Jaguar Health in the Treatment of Short Bowel Syndrome (SBS)Accesswire • 09/13/23
Napo Pharmaceuticals, a Jaguar Health Family Company, Submits Funding Application to National Institute of Allergy and Infectious Diseases for Development of NP-300 Drug Candidate for Cholera-Related DiarrheaAccesswire • 09/12/23
Jaguar Health Shares Replay Link for September 7, 2023 Presentation at Emerging Growth ConferenceAccesswire • 09/11/23
Jaguar Health's Executive VP Dr. Karen Brunke Joins BIO's Rare Disease and Orphan Drugs CommitteeAccesswire • 09/07/23
The Science Times Publishes Article About Jaguar Health's Focus on Developing Crofelemer for Two Rare Disease IndicationsAccesswire • 08/30/23
Jaguar Health to Present September 7 at Emerging Growth Conference and at the September 11-13 H.C. Wainwright Annual Global Investment ConferenceAccesswire • 08/28/23
Jaguar Health Engages B2i Digital to Deploy Cutting-Edge Investor Engagement CampaignAccesswire • 08/24/23
Napo Pharmaceuticals, a Jaguar Health Family Company, Reports Completion of Last Patient Last Visit for its Pivotal Phase 3 OnTarget Trial of Crofelemer for Preventive Treatment of Cancer Therapy-Related DiarrheaAccesswire • 08/17/23
Napo Pharmaceuticals Surveys of Neurologists, Patients, and Caregivers Regarding Amyotrophic Lateral Sclerosis (ALS) Treatment Indicate Real World Burden of Diarrhea and Potential Treatment InterruptionAccesswire • 08/16/23
Jaguar Health to Hold Investor Webcast Monday, August 14th at 8:30 AM EDT Regarding Q2 2023 Financials & Corporate UpdatesAccesswire • 08/10/23
Napo Pharmaceuticals, a Jaguar Health Family Company, Submits Funding Application to BARDA for Development of NP-300 Drug Candidate for Cholera-Related DiarrheaAccesswire • 08/09/23
Napo Pharmaceuticals, a Jaguar Health Company, Announces Activation by FDA of Investigational New Drug (IND) Application for Crofelemer for Treatment of Microvillus Inclusion DiseaseAccesswire • 08/08/23
Independent Study Published in Clinical Breast Cancer Shows Activity of Jaguar Health's Crofelemer for Neratinib-induced DiarrheaAccesswire • 08/07/23
Jaguar Health to Present Aug 4th at Wall Street Wonders Investment Group Luncheon in NYCAccesswire • 08/03/23
Jaguar Health Announces FDA Activation of Third-Party Investigational New Drug (IND) Application for Evaluation of Crofelemer for Treatment of Uncontrolled Diarrhea in Patient with Short Bowel Syndrome (SBS)Accesswire • 08/01/23
Jaguar Health Names Principal Investigators for Clinical Trial to Support Full Approval of Canalevia-CA1 for Treatment of Chemotherapy-Induced Diarrhea (CID) in DogsAccesswire • 07/26/23
Jaguar Health Reports Approval of All Proposals at 2023 Annual Meeting of StockholdersAccesswire • 07/07/23
Napo Pharmaceuticals, a Jaguar Health Company, Submits Investigational New Drug (IND) Application to FDA for Microvillus Inclusion DiseaseAccesswire • 06/28/23
First U.S.-Based Canine Cancer Registry, Founded by Jaguar Health, Joins International Network to Help Advance Canine and Human Cancer ResearchAccesswire • 06/26/23
Jaguar Health Launching AI-Driven Social Media Disease Awareness Education Series Regarding Cancer Therapy-Related Diarrhea in Dogs and PeopleAccesswire • 06/22/23
Jaguar Health Subsidiary Becomes Corporate Partner of Multinational Association of Supportive Care in Cancer (MASCC)Accesswire • 06/20/23
Ladenburg Thalmann to Host Virtual Discussion June 22nd with Jaguar Health CEO and Leading Patient Advocates on Impact of Cancer Therapy-related Diarrhea on Patients & Importance of the Patient Voice in Supportive CareAccesswire • 06/14/23
